Nanohsa (Human Albumin Solution)

Human albumin increases plasma oncotic pressure, drawing water from the interstitial space into the bloodstream. This expands the circulating blood volume, improves tissue perfusion, and supports the transport of various substances throughout the body.

The dose of Nanohsa is determined by the prescribing clinician based on the patient’s clinical condition, weight, and required volume expansion. The prescriber will calculate the appropriate volume to administer.

The safety of Nanohsa in pregnancy or while breastfeeding has not been definitively established. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To order Nanohsa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nanohsa provides natural human albumin, which offers oncotic support and binding capacity not present in synthetic colloids. Compared with crystalloids, albumin expands plasma volume more efficiently with less total fluid required, but it is generally more expensive and requires careful monitoring for volume overload.

Nanohsa should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the vial in its original packaging until use to maintain sterility and stability.

Nanohsa is supplied as a sterile solution for injection and can be given via intradermal, intratumoral, or subcutaneous routes, depending on the clinical indication. Administration is performed by qualified healthcare professionals under aseptic conditions.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, and thromboembolic events. Patients should be closely monitored for signs of respiratory distress, sudden hypotension, or unexpected swelling during and after infusion.

Nanohsa should be avoided in patients with known hypersensitivity to human albumin, uncontrolled heart failure, severe renal impairment where fluid overload is a concern, or in those where volume expansion could exacerbate existing conditions.